Clinical Trial
Published on 29 Jul 2024
Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalency clinical trial
in Vaccines and Molecular Therapeutics
![Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalency clinical trial](https://www.frontiersin.org/files/myhome article library/1425906/1425906_Thumb_400.jpg)
- 439 views